Novel complementing receptor-ligand pairs and adoptive immunotherapy using the same

• US 20050069960A1
• Filed: 11/19/2004
• Published: 03/31/2005
• Est. Priority Date: 03/20/1998
• Status: Abandoned Application

• Current Assignee: Charles A. Nicolette
• Original Assignee: Charles A. Nicolette
• Inventors: Nicolette, Charles A.
• Application Number:
  US10/993,841
• Publication Number:
  US 20050069960A1
• Time in Patent Office: Days
• US Class Current: 435/7.200
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 38/217 IFN-gamma
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/4635 Cytokines
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 2333/525 Tumor necrosis factor [TNF]
• CPC Class Codes: G01N 2333/535 Granulocyte CSF; Granulocyte-macrophage CSF
• CPC Class Codes: G01N 2333/55 IL-2
• CPC Class Codes: G01N 2333/57 IFN-gamma
• CPC Class Codes: G01N 2333/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5011 : for testing antineoplastic activity
• CPC Class Codes: G01N 33/5047 : Cells of the immune system
• CPC Class Codes: G01N 33/5073 : Stem cells
• CPC Class Codes: G01N 33/5091 : for testing the pathological state of an organism

Abstract

This invention provides a screen to identify novel therapeutic receptor-ligand pairs. In one embodiment, the receptor-ligand pairs identified by this method induce proliferation of tumor-infiltrating lymphocytes without systemic toxicity associated with the administration of wild-type cytokines. Diagnostic and therapeutic methods using the cytokine-receptor pairs identified by this screen also are provided.

Claims

1. A method for identifying novel receptor-ligand binding pairs, comprising contacting a cell expressing a mutated receptor with a putative ligand and assaying for receptor-ligand binding and biological response and binding of higher affinity as compared to the corresponding wild-type receptor.

2. The method of claim 1, wherein the ligand is a cytokine.

3. The method of claim 2, wherein the mutated receptor selected from the group consisting of mutated IL-2, mutated G-CSF, mutated TNF-α

, and mutated IFN-γ

receptor.

4. The method of claim 1, wherein the putative ligand is selected from the group consisting of IL-2, G-CSF, TNF-α

and IFN-γ

.

5. The method of claim 1, wherein the ligand is the corresponding mutated ligand.

6. The method of claim 1, further comprising purifying the mutated receptor.

7. The method of claim 1, further comprising purifying the mutated ligand.

8. The method of claim 6, further comprising isolation and determining the sequence of the receptor.

9. The method of claim 7, further comprising isolation and determining the sequence of the ligand.

21. A polynucleotide encoding a mutated receptor identified by the method of claim 1.

22. A polynucleotide encoding a mutated ligand identified by the method of claim 1.

29. The method of claim 2, wherein endogenous IL-2 receptor β

activity is blocked during said selection step.

32. The method of claim 1, wherein said expressed mutant IL-2 is a human IL-2 selected from the group consisting of human IL-2 with lysine35 mutated to alanine, human IL-2 with arginine38 mutated to leucine, human IL-2 with phenylalanine42 mutated to lysine, human IL-2 with lysine43 mutated to glutamine, human IL-2 with tryptophan121 mutated to serine, human IL-2 with cysteine58 mutated to serine, human IL-2 with leucine17 mutated to asparagine, or human IL-2 with aspartic acid20 mutated to lysine.

33. The method of claim 2, wherein said expressed mutant IL-2 receptor β

is selected from the group consisting of IL-2 receptor β

H133A, IL-2 receptor β

H133D, or IL-2 receptor β

H133K.

34. The method of claim 1, further comprising isolation and determining the sequence of the recovered IL-2 receptor β

mutant.

35. The method of claim 2, further comprising determining the sequence of the recovered IL-2 mutant.

36. The method of claim 4, further comprising determining the sequence of the recovered IL-2 receptor β

mutant.

37. The method of claim 5, further comprising determining the sequence of the recovered IL-2 mutant.

10. A method of activating a receptor comprising administering to a subject an effective amount of a host cell expressing a polynucleotide encoding a mutated receptor and an effective amount of a ligand that selectively binds to the receptor wherein the receptor is activated by the binding of said ligand to said receptor.

11. The method of claim 10, wherein the ligand is a cytokine.

12. The method of claim 11, wherein the cytokine is selected from the group consisting of IL-2, G-CSF, TNF-α

and IFN-γ

.

13. The method of claim 10, wherein the host cell is a tumor infiltrating lymphocyte or a hematopoietic stem cell.

14. The method of claim 10, wherein the polynucleotide comprises a sequence coding for an IL-2 β

chain and a sequence coding for an IL-2 α

chain.

15. The method of claim 10, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

16. The method of claim 10, wherein the cell is a hematopoietic stem cell and the polynucleotide encodes mutated G-CSF.

20. The method claim 15 or 18, wherein the co-stimulatory molecule is administered as a polynucleotide encoding the molecule.

24. The method of claim 14, wherein the IL-2 β

chain sequence encodes for IL-2 β

H133A and the ligand is selected from the group consisting of mIL-2 334K, hIL-2 D20K, mIL-2 D34H, or hIL-2 D20H.

25. The method of claim 14, wherein the IL-2 β

chain sequence encodes for IL-2 β

H133D and the ligand is selected from the group consisting of mIL-2 334K, hIL-2 D20K, mIL-2 D34H, or hIL-2 D20H.

26. The method of claim 14, wherein the IL-2 β

chain sequence encodes for IL-2 β

H133K and the ligand is selected from the group consisting of mIL-2 334K, hIL-2 D20K, mIL-2 D34H, or hIL-2 D20H.

17. A method of inducing an immune response in a subject bearing a tumor comprising the steps of:

administering to said tumor an effective amount of a polynucleotide encoding a mutated IL-2 receptor and

activating said mutated IL-2 receptor by means of locoregionally administering a mutated ligand that selectively binds to the mutant receptor.

18. The method of claim 17, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

19. The method claim 18, wherein the polynucleotide is administered via a viral vector that is directly injected into the tumor of the subject.

23. A method for selectively activating cytokine expression in a subject comprising the steps of:

administering to said subject an effective amount of a host cell(s) expressing a polynucleotide encoding a mutated receptor and administering an effective amount of a ligand that selectively binds to said mutated receptor activating cytokine expression in said host cell(s).

38. The method of claim 23, wherein the polynucleotide comprises a sequence coding for an IL-2 β

H133A chain and a sequence coding for an IL-2 α

chain and wherein the ligand is selected from the group consisting of mIL-2 334K, hIL-2 D20K, mIL-2 D34H, or hIL-2 D20H.

39. The method of claim 23, wherein the polynucleotide comprises a sequence coding for an for IL-2 β

H133D and a sequence coding for an IL-2 α

chain and wherein the ligand is selected from the group consisting of mIL-2 334K, hIL-2 D20K, mIL-2 D34H, or hIL-2 D20H.

40. The method of claim 23, wherein the polynucleotide comprises a sequence coding for an for IL-2 p H1133K and a sequence coding for an IL-2 a chain and wherein the ligand is selected from the group consisting of mIL-2 334K, hIL-2 D20K, mIL-2 D34H, or hIL-2 D20H.

27. A method for identifying mutant IL-2 receptor-ligand binding pairs, comprising:

1) introducing a plurality of polynucleotides encoding for IL-2 receptor β

mutants into an IL-2 dependent cell that expresses a mutant IL-2, and

2) selecting said cells that survive in the absence of IL-2, and

3) from said surviving cells, recovering the polynucleotides encoding for said IL-2 receptor β

mutants, wherein said mutant IL-2 and said recovered IL-2 receptor β

mutant bind each other and provide the biological response of the wild-type IL-2 ligand-receptor pair.

28. A method for identifying mutant IL-2 receptor-ligand binding pairs, comprising:

1) introducing a plurality of polynucleotides encoding for IL-2 mutants into an IL-2 dependent cell that expresses a mutant IL-2 receptor β

, and

2) selecting said cells that survive in the absence of IL-2, and

3) from said surviving cells, recovering the polynucleotides encoding for said IL-2 receptor β

mutants, wherein said mutant IL-2 and said recovered IL-2 receptor β

mutant bind each other and provide the biological response of the wild-type IL-2 ligand-receptor pair.

30. A method for identifying mutant IL-2 receptor-ligand binding pairs, comprising:

1) providing cells comprising a reporter gene operatively linked to an upstream activating sequence recognized by a selected transcription factor, and expressing an IL-2 mutant fused to the DNA binding domain of said transcription factor and,

2) introducing a plurality of polynucleotides encoding for IL-2 receptor β

mutants fused to the activation domain of said transcription factors into said cell and,

3) selecting the cells that then express said reporter gene, and

4) recovering the polynucleotides encoding for said IL-2 receptor β

mutant fusion proteins from said expressing cells,

wherein said recovered IL-2 receptor β

mutant interacts with the mutant IL-2 ligand.

31. A method for identifying mutant IL-2 receptor-ligand binding pairs, comprising:

1) providing cells comprising a reporter gene operatively linked to an upstream activating sequence recognized by a selected transcription factor, (need something here?,) and expressing an IL-2 receptor β

mutant fused to the DNA binding domain of said transcription factor and,

2) introducing a plurality of polynucleotides encoding for IL-2 mutants fused to the activation domain of said transcription factors into said cell and,

3) selecting the cells that then express said reporter gene, and

4) recovering the polynucleotides encoding for said IL-2 mutant fusion proteins from said expressing cells, wherein said recovered IL-2 receptor β

mutant interacts with the mutant IL-2 ligand.